首页 正文

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort

{{output}}
Introduction: With an additional year of follow-up compared with the previous report, this study presents the 27.2-month efficacy and safety outcomes of the MajesTEC-1 China cohort. ... ...